The nicotine gum market has seen considerable growth due to a variety of factors.
•The market size for nicotine gum has seen significant expansion in the past few years. The market value is projected to increase from $1.75 billion in 2024 to $1.84 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%.
The historic growth of this market can be traced back to efforts such as anti-smoking public health initiatives, regulatory backing for aids to quit smoking, recommendations from doctors, and the general public's preference for self-help strategies to kick the habit.
The nicotine gum market is expected to maintain its strong growth trajectory in upcoming years.
• The market for nicotine gum is anticipated to experience significant expansion in the coming years, with a projection to reach $2.36 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 6.4%.
This growth during the forecasted period can be linked to numerous factors such as worldwide campaigns against smoking, emphasis on mental health and addiction management, stricter e-cigarette regulations, and growing awareness among consumers about health. The forecast period is also expected to witness some major trends such as the introduction of flavored nicotine gums, formulation advancements, the rise of telemedicine and remote support services, and partnerships with healthcare professionals.
The escalating count of fatalities due to smoking is predicted to spur the expansion of the nicotine gum market. Inhaling and discharging gases from the combustion of plant substances such as tobacco, marijuana, or hashish in cigarettes, cigars, or pipes is what constitutes smoking. Nicotine gum offers a solution to this through nicotine replacement therapy (NRT), which supplies a controlled quantity of nicotine without the harmful compounds present in tobacco smoke. This helps individuals quit smoking or minimize their tobacco consumption. The gum can be consumed every 2 hours individually to lessen withdrawal symptoms or it can be optional with a nicotine patch to manage intense cravings. For example, in May 2023, the US-based public health organization, the Centers for Disease Control and Prevention (CDC), stated that cigarette smoking is the leading source of preventable disease, impairments, and deaths in the United States, accruing over 480,000 deaths annually, equating to around one in every five deaths. Additionally, in May 2022, as per the Switzerland-based international health organization, World Health Organization, tobacco claims the lives of over 8 million individuals every year. Remarkably, around 7 million of these deaths are direct consequences of tobacco usage, while roughly 1.2 million deaths occur due to passive exposure to tobacco smoke. Consequently, the increasing death toll from smoking propels the evolution of the nicotine gum market.
The nicotine gum market covered in this report is segmented –
1) By Type: 2 Mg Nicotine Gum, 4 Mg Nicotine Gum, 6 Mg Nicotine Gum
2) By Category: Flavored, Plain
3) By Distribution Channel: Retail Pharmacies, Specialty Stores, Online Stores, Other Distribution Channels
4) By Application: Withdrawal Clinics, Medical Practice, Individual Smokers, Other Applications
Subsegments:
1) By 2 Mg Nicotine Gum: Regular Flavor, Mint Flavor, Other Flavors (Fruit, Cinnamon)
2) By 4 Mg Nicotine Gum: Regular Flavor, Mint Flavor, Other Flavors
3) By 6 Mg Nicotine Gum: Regular Flavor, Mint Flavor, Other Flavors
One major trend capturing the attention in the nicotine gum industry is strategic collaborations. Key players in this market are keen on establishing strategic partnerships to bolster their market position. For example, in March 2022, Nicorette, a smoking cessation brand from the US which produces nicotine gums, entered into a partnership with Nicoderm CQ, a subsidiary of the US-based biopharmaceutical company, GSK Consumer Healthcare. This collaboration enabled both companies to introduce a renewed brand outlook, inclusive of new visual brand language and distinct assets, with the aim of creating a more personalized, inclusive and emotionally appealing engagement with clients on all platforms. The goal is to efficiently address the growing needs of smokers by providing nicotine replacement therapy (NRT) solutions geared towards a nicotine-free end. Similarly, in February 2022, Enorama Pharma AB, a pharmaceutical company based in Sweden, joined forces with Betapharm Arzneimittel GmbH for releasing a generic nicotine gum in Germany under the brand, Nicotine beta. The company is also developing an online smoking cessation program. Betapharm Arzneimittel GmbH is a pharmaceutical corporation based in Germany.
Major companies operating in the nicotine gum market include:
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Johnson & Johnson
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Novartis AG
• Alchem International Pvt Ltd.
• Fertin Pharma A/S
• British American Tobacco plc
• ITC Limited
• Revolymer plc
• Chemnovatic Sp. z o.o.
• The Himalaya Drug Company
• Nicotinell Ltd.
• The Harmless Cigarette Company
• GN Tobacco Sweden AB
• Niconovum AB
• Perrigo Nicotine Lozenges
• Rugby Laboratories
• Enorama Pharma AB
• NicoBloc Ltd.
• V&YOU
• BGP Healthcare
• Tobacco Technology Inc.
• IVL Group
North America was the largest region in the nicotine gum market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nicotine gum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.